Array BioPharma to Report Financial Results for the Second Quarter of Fiscal 2014 on February 4, 2014

BOULDER, Colo., Jan. 29, 2014 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the second quarter of fiscal 2014 and hold a conference call to discuss those results on Tuesday, February 4, 2014.  Ron Squarer, Chief Executive Officer and Michael Carruthers, Chief Financial Officer will lead the call.


Conference Call Information


Tuesday, February 4, 2014


9:00 a.m. eastern time


(877) 261-8990


(847) 619-6441

Pass Code:


Webcast, including Replay and Conference Call Slides:

About Array BioPharma

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer.  Seven Phase 3 or pivotal studies are already in progress, or are planned to begin, within the next year. These programs include the wholly-owned hematology drug, filanesib (ARRY-520), for multiple myeloma and two partnered cancer drugs, selumetinib (AstraZeneca) and MEK162 (Novartis).  For more information on Array, please go to


Tricia Haugeto

Array BioPharma Inc.

(303) 386-1193

SOURCE Array BioPharma Inc.


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.


PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.